Healthcare
Live Price
Offline$0.80
+0.00% today
1Y Change
+33.33%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Raffles Medical Group Ltd (RAFLF) is a Healthcare stock with a market cap of $1.83B and listed on OTC. The stock last traded around $0.80 and up 33.3% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +1.8%, EPS growth of +13.7%, a dividend yield of 2.5%. What stands out right now is revenue +1.8%, EPS +13.7%, free cash flow +50.0% with operating margin 10.9% and ROIC 3.9%. The dividend matters to the case here, with a current yield around 2.5%. Valuation already assumes a fairly strong business story at P/E 38.6 and price/sales 3.2. Stock Foundry combines RAFLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAFLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RAFLF Max Drawdown
-13.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RAFLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$723.8M
-12.0% YoY
FY Net Income
$84.2M
-41.2% YoY
Free Cash Flow
$107.2M
-37.3% YoY
Revenue Growth
+1.8%
EPS Growth
+13.7%
Gross Margin
45.7%
Net Margin
8.4%
Income statement
SGD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 765M | 752M | 708M | 823M | 724M |
| Gross Profit | 137M | 486M | 316M | 640M | 581M |
| Operating Income | 91M | 82M | 116M | 196M | 121M |
| EBITDA | 135M | 136M | 133M | 236M | 161M |
| Net Income | 71M | 62M | 90M | 143M | 84M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SGD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 311M | 344M | 344M | 253M | 265M |
| Total Assets | 1.4B | 1.5B | 1.5B | 1.5B | 1.5B |
| Total Liabilities | 374M | 466M | 484M | 467M | 569M |
| Shareholder Equity | 1.1B | 1.0B | 1.0B | 1.0B | 961M |
| Total Debt | 115M | 88M | 125M | 96M | 198M |
| Net Debt | -196M | -256M | -219M | -157M | -67M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
160M
-18.4% YoY
Capital Expenditures
53M
-109.0% YoY
Free Cash Flow
107M
-37.3% YoY
Key ratios
Gross Margin
45.7%
Operating Margin
10.9%
Net Margin
8.4%
ROE
4.6%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.